A practical reference on human growth hormone: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-14 and is reviewed periodically as new material appears.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
=== Velocity measurement === The effect of a mean flow of the gas in the path of the laser beam can be seen as a shift in the absorption spectrum, also known as Doppler shift. The shift in the frequency spectrum is related to the mean flow velocity by,
== Chemistry == The minimum requirement for adrenergic agents is a primary or secondary amine separated from a substituted benzene ring by one or two carbons. This configuration results in strong agonist activity. As the size of the substituent attached to the amine becomes greater, particularly with respect to a t-butyl group, then the molecule typically is found to have receptor affinity without intrinsic activity, and is, therefore, an antagonist. Labetalol, with its 1-methyl-3-phenylpropyl substituted amine, is greater in size relative to a t-butyl group and therefore acts predominantly as an antagonist. The overall structure of labetalol is very polar. This was created by substituting the isopropyl group in the standard beta blocker structure with an aralkyl group, including a carboxamide group on the meta position, and by adding a hydroxyl group on the para position. Labetalol has two chiral carbons and consequently exists as four stereoisomers. Two of these isomers, the (S,S)- and (R,S)- forms are inactive. The third, the (S,R)-isomer, is a powerful α1-adrenergic receptor blocker. The fourth isomer, the (R,R)-isomer which is also known as dilevalol, is a mixed non-selective β-adrenergic receptor blocker and selective α1 blocker. Labetalol is typically given as a racemic mixture to achieve both α- and β-adrenergic receptor blocking activity.
=== Traditional medicine and research === The bark, sap, roots, leaves, seeds, and flowers are used in traditional medicine. Research has examined how it might affect blood lipid profiles and insulin secretion. Extracts from leaves contain various polyphenols, which are under basic research to determine their potential effects in humans. Despite considerable preliminary research to determine if moringa components have bioactive properties, no high-quality evidence has been found to indicate that it has any effect on health or diseases.
As Louisiana treasurer, Kennedy defended his choice to invest state money in Israeli bonds, writing, "Here’s how the U.S. Secretary of State’s Office sums up our nation's relationship with Israel: 'The United States was the first country to recognize Israel as a state in 1948. Since then, Israel has become, and remains, America's most reliable partner in the Middle East. Israel and the United States are bound closely by historic and cultural ties as well as by mutual interests.' That—along with Israel Bonds' solid track record—is good enough for me.” In April 2018, Kennedy was one of eight Republican senators to sign a letter to United States Secretary of the Treasury Steve Mnuchin and acting Secretary of State John Sullivan expressing "deep concern" over a United Nations report exposing "North Korean sanctions evasion involving Russia and China" and asserting that the findings "demonstrate an elaborate and alarming military-venture between rogue, tyrannical states to avoid United States and international sanctions and inflict terror and death upon thousands of innocent people" while calling it "imperative that the United States provides a swift and appropriate response to the continued use of chemical weapons used by Syrian President Bashar al-Assad and his forces, and works to address the shortcomings in sanctions enforcement." In January 2019, Kennedy was one of 11 Republican senators to vote to advance legislation intended to block Trump's intent to lift sanctions against three Russian companies.
== References == Brendon, Piers (2010). The Decline and Fall of the British Empire, 1781–1997 (1st Vintage books ed.). New York City: Vintage Books. ISBN 9780307388414. Cilliers, Jakkie (1985). Counter-Insurgency in Rhodesia (PDF). Beckenham, United Kingdom: Croom Helm. ISBN 0-7099-3412-2. Cline, Lawrence E. (2005). "Pseudo Operations and Counterinsurgency: Lessons from Other Countries" (PDF). Strategic Studies Institute, US Army War College. Cross, G. (2017). Dirty War: Rhodesia and Chemical Biological Warfare, 1975–1980. Helion & Company. ISBN 978-1-911512-12-7. Dzimbanhete, Jephias Andrew (March 2017). "Reverberations of Rhodesian Propaganda in Narratives of Zimbabwe's Liberation War". Journal of Pan African Studies. 10 (1): 295–307. Evans, Michael (June 2007). "The Wretched of the Empire: Politics, Ideology and Counterinsurgency in Rhodesia, 1965–80". Small Wars & Insurgencies. 18 (2): 175–195. doi:10.1080/09574040701400601. S2CID 144153887. Gatchel, Theodore L. (2008). "Pseudo Operations – A Double Edged Sword of Counterinsurgency". In Norwitz, Jeffery H. (ed.). Armed Groups: Studies in National Security, Counterterrorism, and Counterinsurgency. Newport, Rhode Island: US Naval War College. pp. 61–74. ISBN 9781884733529. Martinez, Ian (December 2002). "The History of the Use of Bacteriological and Chemical Agents during Zimbabwe's Liberation War of 1965–80 by Rhodesian Forces". Third World Quarterly. 23 (6): 1159–1179. doi:10.1080/0143659022000036595. ISSN 0143-6597. JSTOR 3993569. S2CID 145729695. McLaughlin, Peter (August 1991).
Sources: en.wikipedia.org
Brown bread, in contrast to white bread, is bread made with significant amounts of whole grain flours, usually wheat sometimes with corn and or rye flours. In some countries brown breads often get their characteristic dark color from ingredients such as molasses or coffee. In Canada, the UK, Ireland and South Africa, it is a blend of white flour and whole wheat flour. Wholemeal bread within the UK must be made solely from whole wheat flour. In New England and the Maritimes, brown bread is bread sweetened with molasses.
== Structural properties == Traditionally, PPII has been considered to be relatively rigid and used as a "molecular ruler" in structural biology, e.g., to calibrate FRET efficiency measurements. However, subsequent experimental and theoretical studies have called into question this picture of a polyproline peptide as a "rigid rod". Further studies using terahertz spectroscopy and density functional theory calculations highlighted that polyproline is in fact much less rigid than originally thought. Interconversions between the PPII and PPI helix forms of poly-proline are slow, due to the high activation energy of X-Pro cis-trans isomerization (Ea ≈ 20 kcal/mol); however, this interconversion may be catalyzed by specific isomerases known as prolyl isomerases or PPIases. The interconversion between the PPII and PPI helices involve the cis-trans peptide bond isomerization along the whole peptide chain. Studies based on ion-mobility spectrometry revealed existence of a defined set of intermediates along this process.
=== Social Impact === Alongside his management roles with Nando's, co-founder Robert Brozin has been involved in various social-impact initiatives. He founded Goodbye Malaria, an initiative supporting malaria-elimination programmes in southern Africa and was involved in establishing the Harambee Youth Employment Accelerator, which works to improve employment opportunities for young people in South Africa. Brozin has also supported initiatives focused on revitalisation of Johannesburg's inner city and the future of Chris Hani Baragwanath Academic Hospital. His philanthropic work has been recognised within South Africa's Jewish community, including through his receiving the 2023 Kirsh Family Lifetime Achievement Award in honour of Helen Suzman at the Absa Jewish Achiever Awards.
=== South Slavic === Sloga Fraternal Life Insurance Society - Founded in 1897 as the South Slavic Benevolent Union. Adopted the name Sloga Fraternal Life Insurance Society in 1968. Headquarters in Milwaukee. In 1978 it was noted that "in recent years non-Slovanians [sic] also are eligible for membership" as well as non-Catholics. 1978 membership was 1,400 in 14 lodges. 1995 membership 2,247. In the late 1970s it was reported to sell insurance only in Wisconsin. By the late 1990s, they were reported to sell insurance "principally" in Wisconsin. It awards scholarships to members, conducts blood drives, and participates and bowling and softball. Members are encouraged to contribute to community charities such as United Fund and Easter Seals. Merged with Croatian Fraternal Union in 1994. Western Slavonic Association
Sources: en.wikipedia.org
== Operations == A&W is the only major fast-food chain in the United States to be owned entirely by franchisees since the 2011 sale from Yum! Brands to A Great American Brand, LLC., which is mostly under the control of the National A&W Franchisee Association (NAWFA). The current owners rely heavily on single-brand restaurants, in contrast to combined, co-branded restaurants, which came from prior administrations. As of December 2021, there were 900 restaurants in the US and Asia. In the United States alone, the states with the most restaurants are California, followed by Wisconsin and Michigan. As of year-end 2023, A&W has 455 franchised restaurants in the US market alone. The number of co-branded locations has been on the decline with 243 such units. As of January 2025, A&W has made it to the Franchise 500 list for six consecutive years, standing at 210th place in the 2024 ranking. The number of restaurants in the United States and in Asia is almost equiparable, with the chain steadily decreasing its number of units in the United States and increasing elsewhere, a trend that has been following since 2015.
A complex authority structure; An extensive division of labor between classes within the organization; Meritocratic (as opposed to cultural or social attributes); Responsibilities carried out in an impersonal manner; Extensive written rules/regulations (as opposed to cultural praxis dictating action); and, 'Top-down' communication and rule enforcement mechanisms. However, this model of operation has some flaws:
J. Charles Jennette is a physician, nephropathologist, academic, and author. He served as Kenneth M. Brinkhous Distinguished Professor and Chair of Pathology and Laboratory Medicine at the University of North Carolina at Chapel Hill School of Medicine, and Chief of Pathology and Laboratory Medicine Services at UNC Hospitals from 1999 to 2019. Jennette's research focuses on understanding the causes of kidney diseases, particularly those induced by inflammatory and immunologic mechanisms, and improving the diagnosis and treatment of these diseases. He has authored and edited books, book chapters and articles in medical journals, and is an editor of four editions of the nephropathology textbook titled Heptinstall's Pathology of the Kidney. He has more than 25 named lectureships including the UNC School of Medicine 2015 Norma Berryhill Distinguished Lecture. He is the recipient of the Order of the Long Leaf Pine Award from the Governor of North Carolina for exemplary service to the State, Distinguished Service Award of the Association of Pathology Chairs, UNC Medical Alumni Distinguished Faculty Award, and Robert H. Heptinstall Lifetime Achievement Award from the Renal Pathology Society. Jennette served as the founding Secretary Treasurer of the Renal Pathology Society from 1993 until 1998, was elected vice president in 2003, and became president in 2004. He also served as President of the Association of Pathology Chairs from 2008 until 2010.
== Continuous flow fast atom bombardment == In continuous flow fast atom bombardment (CF-FAB), the sample is introduced into the mass spectrometer insertion probe through a small diameter capillary. (CF)-FAB was developed to minimize the problem of poor detection sensitivity that is caused by an excess of the matrix background that results in a high matrix-to-sample ratio. When a metal frit is used to disperse the liquid on the probe, the technique is known as frit FAB. Samples can be introduced by flow injection, microdialysis, or by coupling with liquid chromatography. Flow rates are typically between 1 and 20 μL/min. CF-FAB has a higher sensitivity compared to static FAB
Rausing strove to improve the Tetra Classic system, beset with many technical problems during the 1950s, and spent enormous amounts on development. The different projects – the tetrahedron, the aseptic packaging technology, Tetra Brik – all demanded large resources, and the company had financial troubles well into the 1960s. Tetra Pak's commercial breakthrough did not arrive until the mid-1960s with the new Tetra Brik package, introduced in 1963, and the development of the aseptic technology. To liberate capital, Åkerlund & Rausing was sold in 1965 while AB Tetra Pak was retained. International expansion had begun in the 1960s, when the first production plant outside of Sweden was established in Mexico in 1960, soon to be followed by another in the United States in 1962. In 1964, the first Tetra Classic Aseptic machine outside of Europe was installed in Lebanon. The late-1960s and 1970s saw a global expansion of the company, mainly due to the new Tetra Brik Aseptic package, launched in 1969, which opened up new markets in the developing world and sparked an explosion in sales.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.